
Sign up to save your podcasts
Or


Join Kate, Mark, Gary and Henry as they discuss whether we should (or can) use biomarkers to predict mild cognitive impairment or dementia, financial incentives to promote smoking cessation, the efficacy of HP eradication for functional dyspepsia, and results of the glycemic control arm of the GRADE Trial.
By Mark Ebell4.7
9292 ratings
Join Kate, Mark, Gary and Henry as they discuss whether we should (or can) use biomarkers to predict mild cognitive impairment or dementia, financial incentives to promote smoking cessation, the efficacy of HP eradication for functional dyspepsia, and results of the glycemic control arm of the GRADE Trial.

137 Listeners

703 Listeners

498 Listeners

289 Listeners

287 Listeners

263 Listeners

3,339 Listeners

1,151 Listeners

191 Listeners

88 Listeners

513 Listeners

367 Listeners

249 Listeners

372 Listeners

315 Listeners